News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
Clinical - Phase I
Atara Biotherapeutics (ATRA) Doses First Patient In Phase 1 Clinical Study Of STM 434, An Activin Inhibitor 10/22/2014
Johnson & Johnson (JNJ) Pledges $200 Million To Ebola, Will Begin Testing Vaccine In January 2015 10/22/2014
Athera Biotechnologies Initiates Phase I Trial With Its Fully Human Antibody PC-mAb 10/21/2014
Cornerstone Pharmaceuticals, Inc. Initiates Phase I Clinical Trial Of CPI-613 For The Treatment Of Hodgkin's Or T-Cell Non-Hodgkin's Lymphoma 10/21/2014
Generex Biotechnology Corporation (GNBT) Announces Publication Of Ebola Vaccine White Paper By Antigen Express, Inc. (GNBT) 10/21/2014
Agios Pharmaceuticals (AGIO) Announces Initiation Of A Phase 1/2 Clinical Trial Of AG-221 In Patients With Advanced Solid Tumors With An IDH2 Mutation 10/21/2014
ChemoCentryx, Inc. (CCXI)'s Orally Administered CCR9 Inhibitor, CCX507, Shown To Be Well Tolerated And Effective In CCR9 Blockade In Phase I Study 10/21/2014
Ebola Clinical Trials: Big Name Players In The Ebola Race 10/20/2014
Novartis AG (NVS)'s Leukemia Drug CTL01 Clears Cancer In 90 Percent Of Patients 10/20/2014
AgonOx’s OX40 Platform Being Utilized In MedImmune (AZN)’s Phase 1 OX40 Agonist Study 10/20/2014
R-Tech Ueno: Announcement Of Initiation Of The Phase I Clinical Trial For The Novel VAP-1 Inhibitor RTU-1096 10/20/2014
Milo Biotechnology's Follistatin Gene Therapy Increases Function In Becker Muscular Dystrophy Patients 10/20/2014
Galapagos NV (GLPG.BR) Discloses Novel Target And Presents Favorable Phase 1 Data For GLPG1205 At UEG Week 10/20/2014
Sarepta Therapeutics (SRPT) Announces Publication Of Ebola And Marburg Phase 1 Clinical Study Results; Contract With BioDefense Therapeutics 10/17/2014
GlobeImmune, Inc. (GBIM) Release: Updated Chordoma Data From Phase 1 Study Of GI-6301 Presented At 2014 Connective Tissue Oncology Society (CTOS) Annual Meeting 10/17/2014
InnFocus Featured at the Ophthalmology Innovation Summit In Chicago 10/17/2014
Ampio Pharmaceuticals, Inc. (AMPE) Announces Results Of The Open Label Portion Of The Multiple Intra-Articular Injections (MI) Study Of Ampion™ In Patients With Osteoarthritis Of The Knee At Week Twelve Of The Trial 10/17/2014
MediGene, Inc. Announces Publication In Cancer Immunology, Immunotherapy On DC Vaccine Development For A Phase 1/2 Trial In Acute Myeloid Leukemia 10/16/2014
Octreopharm Sciences Gets FDA Orphan Drug Designation For Management Of Neuroendocrine Tumors 10/16/2014
Stemline Therapeutics, Inc. (STML) Initiates SL-401 Trial In AML Patients In First Complete Response With Minimal Residual Disease, The Second SL-401 Trial Initiated In 2H14 10/16/2014
Advanced Cell Technology Announces Positive Results from Two Clinical Trials Published In Lancet Using Differentiated Stem Cell-Derived Retinal Pigment Epithelium (RPE) Cells For The Treatment Of Macular Degeneration 10/15/2014
Sorrento Therapeutics, Inc. Release: Initial Pharmacokinetic Data From TRIBECA Study Support Potential For Bioequivalence Between Cynviloq And Albumin-Bound Paclitaxel 10/15/2014
Cellectar Biosciences  (NVLT) Announces Publication Of Findings Demonstrating Efficacy Of Its Phospholipid Ether Analog Platform In Detecting Colorectal Cancer 10/15/2014
Hanmi Pharmaceutical, Co., Ltd And Collaborative Partner Kinex Pharmaceuticals Announce Preliminary Results From A Phase I Clinical Study (HM-OTE-103) With Oratecan® In Patients With Advanced Cancer 10/15/2014
ActoGeniX Announces Positive Results From A Phase 1 Study Of AG014; Oral Capsule Administration Of An Anti-TNF-Alpha Antibody For The Treatment Of Inflammatory Bowel Disease 10/15/2014
Advaxis, Inc. Provides Clinical Update For Phase 1/2 Trial Of ADXS-HPV Immunotherapy Product Candidate In Anal Cancer 10/15/2014
Agios Pharmaceuticals (AGIO) Announces Initiation Of Four Expansion Cohorts In Phase 1 Study Of AG-221 10/15/2014
Advaxis, Inc.'s Lm-LLO Immunotherapy Data To Be Presented In Three Posters At The Society For Immunotherapy Of Cancer 29th Annual Meeting 10/14/2014
EU-Funded Consortium Led By immatics biotechnologies GmbH And BioNTech To Advance A Novel Class Of Fully Personalized Therapeutic Cancer Vaccines Into Clinical Trials For Brain Cancer 10/14/2014
Targeted Medical Pharma Releases Promising Trial Results For The Treatment Of Posttraumatic Stress Disorder 10/14/2014
Scancell Release: AGM Research And Development Update Highlights Progress In Both SCIB1 Clinical Trial And Moditope® Platform 10/14/2014
bluebird bio (BLUE) Announces First Patient With Sickle Cell Disease Transplanted With LentiGlobin Gene Therapy 10/14/2014
Acceleron Pharma Initiates Phase 1 Clinical Trial With Innovative Muscle Drug ACE-083 10/14/2014
Kineta Inc. Announces The Opening Of The First Psoriasis Clinical Trial Using Novel ShK-186 10/14/2014
Idera Pharmaceuticals, Inc. (IDRA) Expands Pipeline by Initiating Clinical Development of Proprietary TLR Antagonist Candidate IMO-9200 10/14/2014
Vaxart, Inc.’s Tablet Vaccine For H1N1 Influenza Generates Protective Immunity Equivalent To Injectable In Phase I Clinical Study 10/14/2014
Intra-Cellular Therapies, Inc.'s Dementia Drug Meets Phase 1/2 Goals 10/13/2014
Mali Health Workers Get Experimental GlaxoSmithKline (GSK) Ebola Vaccine 10/13/2014
Public Health Agency of Canada Release: Canadian Ebola Vaccine Trials Begin 10/13/2014
Concert Pharmaceuticals, Inc. (CNCE) Presents Positive Data From Multiple Dose Phase 1 Clinical Trial Of CTP-354, Lead Candidate For The Treatment Of Spasticity 10/13/2014
Bioheart, Inc. Announces Positive 12 Month Preliminary Data From Phase I Angel Trial 10/13/2014
Dynavax Technologies Corporation (DVAX) Initiates Phase 1/2 Study Of TLR-9 Agonist Immunotherapy In B-Cell Lymphoma 10/13/2014
Cytokinetics, Inc. (CYTK) Announces Development Program Update For CK-2127107 10/13/2014
CytoDyn Announces 100% Success With PRO 140 In Four-Week Monotherapy Clinical Trial 10/13/2014
Kite Pharma, Inc. (KITE) Announces Patients With Relapsed Or Refractory Acute Lymphoblastic Leukemia (ALL) Experience Positive Results After Receiving Anti-CD19 Chimeric Antigen Receptor (CAR) T Cells 10/13/2014
Momenta Pharmaceuticals, Inc. (MNTA) Announces Top-Line Part A Results From Phase 1/2 Trial Of Necuparanib In Patients With Pancreatic Cancer 10/10/2014
First Patient Treated In NeuralStem Inc. Phase I Spinal Cord Injury Stem Cell Trial Through The University of California, San Diego (UCSD) Sanford Stem Cell Clinical Center 10/9/2014
Regen BioPharma Submits Experimental Protocol To FDA For HemaXellerate Aplastic Anemia Trial 10/9/2014
Bone Therapeutics Extends ALLOB® Phase I/IIa Trial To Germany 10/9/2014
DelMar Pharmaceuticals Release: VAL-083 Demonstrates Promise As A Potential Treatment For Non-Small Cell Lung Cancer 10/9/2014
XOMA (US) LLC (XOMA) Launches XOMA 358 Clinical Development 10/9/2014
CytRx Corporation (CYTR) Initiates Phase 1b Clinical Trial With Combination Of Aldoxorubicin And Gemcitabine In Patients With Metastatic Solid Tumors 10/9/2014
Genocea Biosciences Presents Complete Phase 1/2a Data For HSV-2 Immunotherapy At IDWeek 10/8/2014
Ruthigen Initiates Phase 1/2 Clinical Trial Of RUT58-60 10/8/2014
VaxInnate Corporation Updates Plans To Advance Lead Vaccine Candidate, VAX2012Q In Elderly 10/8/2014
PharmaEngine, Inc. Will Join Nanobiotix' Pivotal Trial For NBTXR3 In Soft Tissue Sarcoma To Accelerate Its Development In Asia-Pacific 10/8/2014
OXiGENE (OXGN) Announces First Patient Enrolled In Phase 1b/2 Study Of Fosbretabulin Combined With Pazopanib In Patients With Advanced Recurrent Ovarian Cancer 10/8/2014
Cornerstone Pharmaceuticals, Inc.' CPI-613 Phase I Hematologic Malignancies Trial Data Published In Clinical Cancer Research 10/7/2014
Cavion And Yale University Announce First Patient Enrolled In Phase 1b Clinical Trial In Brain Cancer 10/7/2014
FDA Grants Clearance To Proceed With Clinical Study – New Drug Candidate From Vivolux Could Overcome Drug Resistance 10/7/2014
Bio-Path Holdings, Inc. (BPTH) Successfully Completes Cohort 6 Of Phase I Clinical Trial Evaluating Liposomal Grb-2 In Blood Cancers 10/7/2014
Debiopharm Group™ Announces Progress In Phase I Single And Multiple Ascending Dose Study Of Debio 1450, Its Potent Anti-Staphylococcal Agent 10/7/2014
Intra-Cellular Therapies, Inc. To Present Results From Phase 1/2 Clinical Trial For ITI-007 In Healthy Geriatric Subjects And Patients With Dementia At The American Neurological Association 139th Annual Meeting 10/7/2014
Ariad Pharmaceuticals, Inc. (ARIA)'s Lung Cancer Drug Wins Breakthrough Therapy Status 10/6/2014
Nitto Denko Corporation (XETRA: ND5.DE): New Anti-Fibrosis Drug With Molecular Targeting DDS Starts Phase-1B Dosing For Cirrhosis Patients 10/6/2014
Antibe Therapeutics Inc. Completes Single Ascending Dose Portion Of ATB-346 Phase I Program 10/6/2014
Prophylix To Commence Phase I/II Trials Of Naitgam (Anti-HPA-1a Immunoglobulin) For The Prevention Of Fetal And Neonatal Alloimmune Thrombocytopenia 10/2/2014
FDA Grants Fast Track Designation To NKT Therapeutics Inc.' NKTT120 For The Treatment Of Sickle Cell Disease 10/2/2014
Heat Biologics Completes Enrollment Of Phase 1 Clinical Trial Of Vesigenurtacel-L For The Treatment Of Bladder Cancer Required To Advance To Phase 2 10/2/2014
Curis, Inc. (CRIS) Announces CUDC-907 Development Program Advancements 10/2/2014
Innate Pharma (IPH.PA ) : Initiation Of A Phase I Clinical Trial Of Lirilumab In Combination With Elotuzumab 10/1/2014
Merck & Co. (MRK)'s Keytruda Shows Positive Signs In Bladder Cancer Trial 9/30/2014
Celldex Therapeutics, Inc. (CLDX) Announces Publication Of Glembatumumab Vedotin Phase 1/2 Studies In The Journal Of Clinical Oncology 9/30/2014
Helix Biopharma (CC:HBP) Reports On Interim Review Of The Polish L-DOS47 Monotherapy Study In Non-Small Cell Lung Cancer 9/30/2014
Sarepta Therapeutics (SRPT) Announces Favorable Safety Results From Phase I Clinical Study Of Influenza Drug Candidate 9/30/2014
Merck & Co. (MRK)'s Keytruda Extends Immune System Fight To Stomach Cancer 9/29/2014
CEL-SCI (CVM) & U.S. Navy Administer Multikine To First Volunteer Patient In Phase I Clinical Trial For Treatment Of Anal Warts In HIV/HPV Co-Infected Patients 9/29/2014
Helix Biopharma (CC:HBP) Initiates Enrollment For Tenth Cohort In Polish Phase I/II Clinical Study Of Its Lung Cancer Drug Candidate L-DOS47 9/29/2014
AstraZeneca PLC (AZN) Release: AZD9291 Shows Durable Clinical Response In Patients With Advanced EGFR Mutation Positive Non-Small Cell Lung Cancer At The ESMO 2014 Congress 9/29/2014
Ignyta (RXDX) Announces Interim Data From RXDX-101 Phase I Clinical Trial At 2014 ESMO Congress 9/29/2014
Ariad Pharmaceuticals, Inc. (ARIA) Presents Updated Clinical Data On AP26113 In Patients With ALK+ Non-Small Cell Lung Cancer 9/29/2014
Cytogel Pharma (Cytogel) Announces Presentation At The 8th Annual Pain And Migraine Therapeutics Summit In Boston On September 24, 2014, Novel Mu Opioid Mechanisms For The Potent Analgesic Cyt-1010 Distinguish It From Morphine 9/29/2014
OncoMed Pharmaceuticals, Inc. (OMED)'s Demcizumab Phase 1b Clinical Trials Show Encouraging Safety And Anti-Tumor Activity At ESMO 9/29/2014
GliaCure Enters First-In-Human Clinical Trial In Alzheimer's Disease 9/26/2014
Pain Therapeutics (PTIE) Expands Pipeline With FENROCK™, An Abuse-Deterrent Pain Patch 9/26/2014
Agios Pharmaceuticals (AGIO) To Present Clinical Data From AG-120 Ongoing Phase 1 Study In Hematologic Malignancies At EORTC-NCI-American Association for Cancer Research 2014 9/26/2014
Seattle Genetics, Inc. (SGEN) Highlights Updated Progression-Free Survival And Overall Survival Data From ADCETRIS® (Brentuximab Vedotin) Frontline PTCL Phase 1 Clinical Trial At The ESMO 2014 Congress 9/25/2014
Blaze Bioscience Inc. Announces Initiation Of Phase 1b Brain Cancer Program For Tumor PaintTM BLZ-100 9/25/2014
Advanced Cell Technology Announces Final Patient Treated In Stargardt’s Macular Degeneration Phase 1 Trial In The United Kingdom 9/25/2014
Rexahn Pharmaceuticals, Inc. (RNN) Receives FDA Orphan Drug Designation For RX-3117 In Treatment Of Pancreatic Cancer 9/25/2014
MabVax Therapeutics, Inc. Receives Orphan Drug Designation For Therapeutic Vaccine To Treat Childhood Cancer Neuroblastoma 9/25/2014
Omnicell Release: First Patients Enrolled In Landmark Clinical Study To Evaluate The Role Of Packaging In Improving Medication Adherence 9/25/2014
TRACON Pharmaceuticals, Inc. Announces Results From Clinical Trials Of TRC105 In Patients With Ovarian Cancer To Be Presented At The 2014 Annual Meeting Of The European Society For Medical Oncology 9/25/2014
Brickell Biotech Announces Positive Preliminary Results Of A Pilot Clinical Study Of BBI-4000 For The Treatment Of Hyperhidrosis 9/24/2014
Inovio Pharmaceuticals (INO) Ebola Vaccine Moving Into Human Trial With GeneOne Life Science 9/24/2014
Novaliq GmbH Reports Positive Results From Cyclasol® (Cyclosporin Solution) Eye Drops Repeated And Ascending Dose Phase 1 Study 9/23/2014
MedImmune (AZN) Receives Fast Track Designation From FDA For Development Of MEDI3902 For Prevention Of Nosocomial Pneumonia 9/23/2014
Novavax, Inc. (NVAX)' H7n9 Avian Influenza VLP Vaccine Candidate With Matrix-M™ Delivers Positive Phase 1/2 Clinical Data 9/23/2014
Promedior Announces Presentation Of Retrospective Quantitative Imaging Analysis Of Phase 1b Data In Idiopathic Pulmonary Fibrosis 9/22/2014
NeuralStem Inc. ALS Investigator Presents Long-Term Follow Up Phase I Data 9/22/2014
Pressure BioSciences, Inc. (BBII) Announces Completion Of The First Phase Of Its Commercialization Plan For The Barozyme HT48, The Company's Recently Released High Throughput PCT-Based Instrument System 9/19/2014
SWOG To Resume Clinical Trial Of Halozyme Therapeutics, Inc. (HALO)'s PEGPH20 In Combination With Modified FOLFIRINOX For Advanced Pancreatic Cancer 9/18/2014
Capricor Therapeutics, Inc. Presents Safety And Preliminary Efficacy Results From ALLSTAR Phase I Clinical Trial At TCT 2014 9/18/2014
Concert Pharmaceuticals, Inc. (CNCE) Announces Initiation Of CTP-730 Phase 1 Clinical Trial Under Celgene (CELG) Collaboration 9/17/2014
Experimental Northwest Biotherapeutics (NWBO) Drug Gets First Slot Under UK Early Access Scheme 9/16/2014
DNAtrix, Inc. Announces Treatment Of First Patient With DNX-2401 In Recurrent Glioblastoma Trial 9/16/2014
Cleveland Biolabs Inc. (CBLI) Announces Approval To Start Phase 1 Study For Hematopoietic Stem Cell Mobilizer CBLB612 In Russian Federation 9/16/2014
TapImmune Inc. (TPIV) Releases Positive Interim Data On Phase I Clinical Trial Of Folate Receptor Alpha Antigens In Ovarian And Breast Cancer 9/16/2014
Virology Publishes Genocea Biosciences HSV-2 Antigen Discovery Paper 9/16/2014
First European Patients Enrolled In QT QT Vascular's ENDURE Trial 9/16/2014
Kolltan Pharmaceuticals Inc. Cancer Study Results For KTN3379, Targeting ErbB3, Support Evaluating Combinations With Targeted Therapies 9/15/2014
Alios BioPharma Presents Data On Its Anti-HCV Nucleotide AL-335 At Special Conference On Hepatitis C 9/15/2014
MEDIPOST America Clears Phase 1/2 IND For The U.S. Clinical Trial On Stem Cell Drug For Lung 9/15/2014
Ultragenyx Pharmaceuticals (RARE) Announces Positive Results From A Long-Term Phase 1/2 Study Of KRN23 In Adult Patients With X-Linked Hypophosphatemia 9/15/2014
Hemispherx Biopharma (HEB)' Drug Ampligen Plus Intranasal Seasonal Influenza Vaccine Induces Cross-Reactive Antibody Formation Against Avian H5N1 And H7N9 Influenza HA In Humans 9/15/2014
to-BBB Announces Positive Data From Phase 1 Clinical Study 9/12/2014
QLT Inc. (QLTI) Announces Positive Final Results From Phase 1b Retreatment Trial With Oral Synthetic Cis-Retinoid (QLT091001) In Subjects With LCA Or RP Due To Mutations In RPE65 Or LRAT 9/12/2014
Synthetic Biologics, Inc. (SYN) Receives Orphan Drug Designation For SYN-005 Treatment For Whooping Cough (Pertussis) 9/11/2014
G1 Therapeutics Initiates Phase 1 Clinical Trial Of G1T28-1 9/11/2014
Cellular Biomedicine Group (CBMG) Completes Twelve-Month Follow-Up Of Patients From Phase 1/2a Clinical Trial For Rejoin™ Therapy For Knee Osteoarthritis 9/10/2014
EMD Group (EMD Millipore (Massachusetts)) Presents New Data on Rebif ® (Interferon beta-1a) And Multiple Sclerosis Pipeline At Joint ACTRIMS-ECTRIMS Meeting In Boston 9/10/2014
CytRx Corporation (CYTR) Initiates Phase 1b Clinical Trial With Combination Of Aldoxorubicin And Ifosfamide/Mesna As First-Line Treatment In Patients With Advanced Sarcomas 9/9/2014
Positive Phase 1a Outcome For Memogain® 9/9/2014
Seres Health Presents Final Data For Study Of SER-109 In Recurrent Clostridium Difficile Infection At ICAAC 2014 Conference 9/9/2014
Lipocine Inc. (LPCN) Announces First Patient Dosed In Phase 1 Study In Pregnant Women Of LPCN 1107, Potentially The First Oral Product For The Prevention Of Preterm Birth 9/9/2014
Redwood City's OncoMed Pharmaceuticals, Inc. (OMED) Moves Forward On Drug Trials Halted Due To Side Effects 9/8/2014
Genocea Biosciences Presents Phase 1 Immunology Data For Novel Pneumoccocus Vaccine At ICAAC 9/8/2014
Shionogi & Co., Ltd. Presents Pre-Clinical And Phase I Results For S-649266, A Novel Siderophore Cephalosporine Antibiotic With Potential To Treat Multidrug-Resistant Gram-Negative Pathogens 9/8/2014
KemPharm, Inc. Advances KP201 Clinical Program With Initiation Of Human Abuse Liability And Human Gastrointestinal Motility Trials 9/8/2014
GenSpera Presents Mipsagargin (G-202) HCC Clinical Trial Update At 8th International Liver Cancer Association Conference 9/8/2014
Sangamo BioSciences, Inc. (SGMO) Announces Presentation At ICAAC Of New Clinical Data Demonstrating Sustained Functional Control Of Viremia In Multiple HIV-Infected Subjects Treated With SB-728-T 9/8/2014
United Therapeutics Corporation (UTHR) Advances To Second Cohort In Phase I Trial Of Pluristem Therapeutics (PSTI)'s PLX-PAD Cells For Treatment Of Pulmonary Arterial Hypertension 9/8/2014
Celsion Corporation (CLSN) Reports Consolidated Duke University And Celsion's DIGNITY Study Clinical Data On Thermodox® In Recurrent Chest Wall Breast Cancer Published In The International Journal Of Hyperthermia 9/5/2014
FDA Give NewLink Genetics Approval To Proceed To Phase 1 Clinical Studies Of Their Ebola Vaccine 9/4/2014
Cleave Biosciences Initiates Phase 1 Clinical Trial Of CB-5083 In Patients With Multiple Myeloma 9/4/2014
Novira Therapeutics Announces Successful Completion Of Phase 1a Clinical Study Of NVR-1221 And Commencement Of Phase 1b Clinical Studies 9/4/2014
Mirati Therapeutics  (MRTX) Initiates Phase 1 Study Of MGCD516 For Non-Small Cell Lung Cancer And Other Advanced Solid Tumors 9/4/2014
VG Life Sciences, Inc. (VGLS) Progress Update Phase I Cancer Study 9/4/2014
Synthetic Biologics, Inc. (SYN) To Initiate Clinical Trials Of SYN-004 In 4Q 2014 To Prevent Potentially Deadly C. difficile Infections 9/3/2014
Soligenix (SNGX) Announces Positive Survival Results With Heat Stable Ricin Toxin Vaccine 9/3/2014
Actinium Pharmaceuticals, Inc. (ATNM.OB) Files Orphan Drug Application For Use Of Actimab-A In The Treatment Of Newly Diagnosed Acute Myeloid Leukemia In Elderly Patients 9/3/2014
Halozyme Therapeutics, Inc. (HALO)'s PEGPH20 Program In Metastatic Pancreatic Cancer Receives Fast Track Designation 9/3/2014
Sabin Vaccine Institute Release: Phase 1 Clinical Trial Of Human Hookworm Vaccine Successfully Completed 9/3/2014
BioLineRx Ltd. Doses First Patient For BL-8040’s Second Indication As Novel Stem Cell Mobilization Treatment 9/3/2014
Ultragenyx Pharmaceuticals (RARE) Announces Positive Interim Data From Phase 1/2 Study Of Recombinant Human Beta-Glucuronidase In Mucopolysaccharidosis 7 9/3/2014
Boston Strategics Corporation Initiates A Phase 1 Clinical Trial Of The Anti-Cancer Agent "FF-10501" For FUJIFILM In Patients With Advanced Hematologic Malignancies 9/2/2014
F2G Ltd, The UK-Based Antifungal Drug Discovery And Development Company, Today Announces Commencement Of A Phase 1 Single Ascending Dose Study Of A Novel Antifungal Agent, F901318. 9/2/2014
Capstone Therapeutics (CAPS) Announces Phase 1a Results For AEM-28 Showing Safety And Biomarker Efficacy Signals 9/2/2014
Catalyst Pharmaceutical Partners, Inc. (CPRX) Initiates Phase 1(B) Safety And Tolerance Study For CPP-115 9/2/2014
OncoMed Pharmaceuticals, Inc. (OMED) Says FDA Lifts Partial Hold On Cancer Drug Trials For Vantictumab 8/29/2014
Senesco Technologies, Inc. (SNT) Closes Enrollment In Its Phase 1b/2a SNS01-T Study 8/29/2014
NIH To Launch Phase I Of GlaxoSmithKline (GSK)'s Ebola Vaccine Candidate; NewLink Genetics VSV-EBOV 8/28/2014
GlaxoSmithKline (GSK)'s Ebola Vaccine To Be Tested For Safety In Humans As Early As Next Week 8/28/2014
Synthetic Biologics, Inc. (SYN) And Fujifilm Diosynth Biotechnologies Announce Significant Improvement In API Manufacturing Of SYN-004 For The Prevention Of C. Difficile 8/28/2014
Telik, Inc. (TELK) Reports Progress Toward Multiple Early Stage Milestones In The Development Of A Novel Antibody-Based Therapeutic Agent For Gastrointestinal Cancers 8/28/2014
Immunotech Laboratories Announces Successful Completion Of Phase 1 And Phase 2 Field Trials Of The Company’s Patented Treatment Of The HIV/AIDS And Hepatitis C Viruses 8/28/2014
BioTime (BTX) Subsidiary Asterias Biotherapeutics Receives FDA Clearance To Initiate Phase 1/2a Clinical Trial Of AST-OPC1 In Patients With Cervical Complete Spinal Cord Injury 8/27/2014
Asterias Biotherapeutics Receives U.S. FDA Clearance To Initiate Phase 1/2a Clinical Trial Of AST-OPC1 In Patients With Cervical Complete Spinal Cord Injury 8/27/2014
Innate Pharma (IPH.PA ) : Orphan Drug Designation In The European Union For Iph4102 8/27/2014
SoCal's Kite Pharma, Inc. (KITE) Shares Fly High On Non-Hodgkin's Lymphoma Drug Study Results 8/26/2014
BeiGene Co.,Ltd Enrolls First Patient In Phase 1 Study Of BGB-3111 8/26/2014
Alkermes plc (ALKS) Announces Initiation Of Phase 1 Clinical Study Of ALKS 7106 For Treatment Of Pain 8/26/2014
Profil Institute for Clinical Research, Inc. Reaches Milestone In Early Phase Clinical Research For Diabetes 8/26/2014
Ruthigen Receives Recommendation From Data Monitoring Committee To Initiate Phase 1/2 Human Clinical Trial Of RUT58-60 8/26/2014
North Carolina's BioKier, Inc. Takes A Shot At A New Kind Of Diabetes Drug 8/25/2014
22nd Annual Susan G. Komen Phoenix Race For The Cure® 2014 Moves To Downtown Phoenix 8/20/2014
KalVista Pharmaceuticals Announces Start Of Clinical Development For Novel Treatment For Diabetic Macular Edema 8/20/2014
NuSirt Biopharma Launches First Clinical Trial 8/20/2014
Oncothyreon Inc. (ONTY)'s Lung Cancer Drug EMR 63325-009 Misses Primary Endpoint In Phase 1 Study 8/20/2014
DelMar Pharmaceuticals Provides Update On Glioblastoma Clinical Trial And Results Of Warrant Tender Offer 8/19/2014
Anavex Life Sciences Corp. (AVXL.OB) Reports That Antidepressant Fluvoxamine Reduces Stress Through Sigma-1 Receptor 8/19/2014
Data Published By Researchers From The Scripps Research Institute Demonstrate Potential For MYC Inhibitor Licensed By Sorrento Therapeutics, Inc. 8/18/2014
MonoSolRx LLC Launches Clinical Study Of MSRX-110 Oral Film For Testosterone Replacement 8/18/2014
TG Therapeutics, Inc. (MHA) Announces Novel "Chemo-Free" Triple Therapy Combination Clinical Study For Patients With Chronic Lymphocytic Leukemia And Other B-Cell Malignancies 8/15/2014
Tekmira Pharmaceuticals Corporation (TKMR)'s Experimental Ebola Drug May Never Reach Africa 8/14/2014
Publication By KaloBios Pharmaceuticals, Inc. (KBIO) And Collaborators Shows EphA3 As Target For Highly Selective Anticancer Therapy 8/14/2014
Alexza Pharmaceuticals, Inc. (ALXA) Provides An Update On The Five Post-EMA Approval Studies For ADASUVE® 8/14/2014
Nuvilex (NVLX) Announces Publication Of Combined Results Of The Initial Phase 1/2 Clinical Trial And A Second Phase 2 Clinical Trial Of The Cell-In-A-Box® Plus Ifosfamide Combination In Patients With Advanced, Inoperable Pancreatic Cancer 8/14/2014
Epizyme (EPZM) Presents Pre-Clinical Data And Early Clinical Observations From Ongoing Phase 1 Trial Of EZH2 Inhibitor EPZ-6438 (E7438) At American Society of Hematology Meeting On Lymphoma Biology 8/13/2014
Agios Pharmaceuticals (AGIO) Announces The U.S. FDA Grants Fast Track Designation To AG-221 For Treatment Of Patients With Acute Myelogenous Leukemia That Harbor An IDH2 Mutation 8/13/2014
GlaxoSmithKline (GSK) Will Take Its Shot At Ebola Later This Year 8/12/2014
Flex Pharma Announces Positive Results From Human Clinical Studies 8/12/2014
Seattle Genetics, Inc. (SGEN) Initiates Phase 1 Clinical Trial Of Antibody-Drug Conjugate SGN-CD70A For Non-Hodgkin Lymphoma And Renal Cell Carcinoma 8/12/2014
Enzymotec Announces Initiation Of A Clinical Study On Autism Spectrum Disorder 8/12/2014
Tekmira Pharmaceuticals Corporation (TKMR) Shares Go Bonkers As Ebola Drug May Be Used On Infected Patients: FDA 8/11/2014
Melinta Therapeutics (Formerly known as Rib-X Pharmaceuticals, Inc.) Reports Top-Line Results Showing Equivalent Exposures After Oral and Intravenous Delafloxacin Administration 8/11/2014
Merrimack Pharmaceuticals Inc. (MACK) Announces Initiation Of HERMIONE, A Randomized Trial Of MM-302 In Patients With Advanced HER2-Positive Breast Cancer To Support Application For Accelerated Approval 8/11/2014
PTC Therapeutics, Inc. (PTCT) Release: Orally Delivered Compounds, Which Selectively Modify RNA Splicing Prevent Deficits In Mouse Models Of Spinal Muscular Atrophy 8/8/2014
FDA Modifies Tekmira (TKMR)'s TKM-Ebola Clinical Hold To Partial Hold 8/7/2014
MD Anderson Cancer Center Postdoc Faked Results Of Novartis AG (NVS) Brain Tumor Study 8/7/2014
TapImmune Inc. (TPIV)'s New Clinical Trial In Advanced Stage Ovarian Cancer Expands The Use Of Folate Receptor Alpha Peptide Antigens 8/7/2014
Alnylam Pharmaceuticals (ALNY) Receives Orphan Drug Designations In The European Union For ALN-AT3, An Rnai Therapeutic In Development For The Treatment Of Hemophilia 8/7/2014
Enanta Pharmaceuticals, Inc.’ HCV NS5A Inhibitor EDP-239 Advances Into Combination Studies With Alisporivir (DEB025) 8/7/2014
Cellceutix (CTIX) Anti-Psoriasis Drug Prurisol Meets Primary Endpoint Of Clinical Trial 8/7/2014
Oramed Pharmaceuticals Inc. (ORMP) Reports Last Patient Out In Phase Iia Trial For ORMD-0801 In Type 1 Diabetes 8/7/2014
Soligenix (SNGX) Advances Development Of A Heat Stable Rapidly Acting Anthrax Vaccine VeloThrax™ 8/7/2014
Trevena, Inc. (TRVN) Initiates Phase 1 Multiple Ascending Dose Study Of TRV734 For Acute And Chronic Pain 8/6/2014
Generex Biotechnology Corporation (GNBT) Announces Publication Of AE37 Prostate Cancer Vaccine Study 8/6/2014
Synthetic Biologics, Inc. (SYN) On Track To Initiate Clinical Program For SYN-004 To Protect Against C. difficile 8/5/2014
NovImmune SA Reports Successful Completion Of Phase I Trial For NI-0101 8/5/2014



//-->